OBJECTIVES: To determine the diagnostic accuracy of fractional exhaled nitric oxide (FENO) measurement in pneumologists routine diagnostic work-up; and to determine the impact of the inflammatory pattern on diagnostic accuracy. METHODS: Prospective diagnostic study in 393 patients attending a private practice of pneumologists with complaints suspicious of obstructive airway disease (OAD). Index test was FENO measurement. Reference standard was the Tiffeneau ratio (FEV(1)/VC) or airway resistance as assessed by whole body plethysmography, with additional bronchoprovocation or bronchodilator testing. Morning sputum was analysed with smear slides which were prepared and stained by Giemsa. RESULTS: 154 patients were diagnosed as having asthma (145 diagnoses based on bronchial provocation, 9 based on bronchodilator results), 5 had COPD. For the whole group, asthma could be ruled in at FENO > 71 ppb (PPV 80%; 95% CI 63-90%) and ruled out at FENO ≤ 9 ppb (NPV 82%; 95% CI 67-91%) (area under the curve (AUC) = 0.656; 95% CI 0.600-0.712; p < 0.001). 128 patients delivered sputum. FENO was 44.3 ppb (sd 48.9) in patients with predominant eosinophilic inflammation, 18.5 ppb with neutrophilic inflammation, and 23.1 ppb in others (p = 0.003). Diagnostic accuracy of FENO increased when patients with neutrophilic inflammation were omitted from analysis (AUC = 0.745; 95% CI 0.651-0.838; p < 0.001). Then asthma could be ruled in at FENO > 31 ppb (PPV 82%; 95% CI 63-92%) and ruled out at FENO ≤ 12 ppb (NPV 81%; 95% CI 62-91%). CONCLUSIONS: FENO measurement can be useful as an additional diagnostic tool in pneumologists' practice. The diagnostic value of FENO could be improved when inflammatory patterns are taken into account.
OBJECTIVES: To determine the diagnostic accuracy of fractional exhaled nitric oxide (FENO) measurement in pneumologists routine diagnostic work-up; and to determine the impact of the inflammatory pattern on diagnostic accuracy. METHODS: Prospective diagnostic study in 393 patients attending a private practice of pneumologists with complaints suspicious of obstructive airway disease (OAD). Index test was FENO measurement. Reference standard was the Tiffeneau ratio (FEV(1)/VC) or airway resistance as assessed by whole body plethysmography, with additional bronchoprovocation or bronchodilator testing. Morning sputum was analysed with smear slides which were prepared and stained by Giemsa. RESULTS: 154 patients were diagnosed as having asthma (145 diagnoses based on bronchial provocation, 9 based on bronchodilator results), 5 had COPD. For the whole group, asthma could be ruled in at FENO > 71 ppb (PPV 80%; 95% CI 63-90%) and ruled out at FENO ≤ 9 ppb (NPV 82%; 95% CI 67-91%) (area under the curve (AUC) = 0.656; 95% CI 0.600-0.712; p < 0.001). 128 patients delivered sputum. FENO was 44.3 ppb (sd 48.9) in patients with predominant eosinophilic inflammation, 18.5 ppb with neutrophilic inflammation, and 23.1 ppb in others (p = 0.003). Diagnostic accuracy of FENO increased when patients with neutrophilic inflammation were omitted from analysis (AUC = 0.745; 95% CI 0.651-0.838; p < 0.001). Then asthma could be ruled in at FENO > 31 ppb (PPV 82%; 95% CI 63-92%) and ruled out at FENO ≤ 12 ppb (NPV 81%; 95% CI 62-91%). CONCLUSIONS:FENO measurement can be useful as an additional diagnostic tool in pneumologists' practice. The diagnostic value of FENO could be improved when inflammatory patterns are taken into account.
Authors: Antonius Schneider; Johannes Schwarzbach; Bernhard Faderl; Hubert Hautmann; Rudolf A Jörres Journal: Dtsch Arztebl Int Date: 2015-06-12 Impact factor: 5.594
Authors: Jean-Luc Malo; Susan M Tarlo; Joaquin Sastre; James Martin; Mohamed F Jeebhay; Nicole Le Moual; Dick Heederik; Thomas Platts-Mills; Paul D Blanc; Olivier Vandenplas; Gianna Moscato; Frédéric de Blay; André Cartier Journal: Ann Am Thorac Soc Date: 2015-07
Authors: Miguel E Quimbar; Steven Q Davis; Sherif T Al-Farra; Amanda Hayes; Valentina Jovic; Maximillian Masuda; Alexander R Lippert Journal: Anal Chem Date: 2020-10-16 Impact factor: 6.986
Authors: Antonius Schneider; Benjamin Brunn; Alexander Hapfelmeier; Konrad Schultz; Christina Kellerer; Rudolf A Jörres Journal: EClinicalMedicine Date: 2022-07-01
Authors: Abraham B Roos; Michiko Mori; Reidar Grönneberg; Christina Österlund; Hans-Erik Claesson; Jan Wahlström; Johan Grunewald; Anders Eklund; Jonas S Erjefält; Jon O Lundberg; Magnus Nord Journal: PLoS One Date: 2014-02-28 Impact factor: 3.240